PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) --PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with…
Read More
ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies See more here
Read More
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors First dual-specific PD-L1/PD-L2 antibody with killing function designed to treat the many immune-excluded cancers that are resistant to existing immunotherapies Phase 1b will focus on tumors that are…
Read More
ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference See more here
Read More
ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers Clinical trials for ImmunoGenesis drug candidates to initiate in 2022 See more here
Read More
Data from ImmunoGenesis' Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference See more here
Read More
ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers Phase 1 canine glioblastoma veterinary trial data show the promise of…
Read More
ImmunoGenesis Expands R&D, Clinical and Business Development Teams and Opens Research Laboratory Clinical and CMC hires to ready initiation of multiple immuno-oncology clinical programs in 2022 Proven business development expertise key to executing global clinical development strategy R&D hires and lab opening to facilitate critical translational research See more here
Read More
ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021. Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer. …
Read More